Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2018-08-06 Director's Dealing
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2018-08-06 English
PRIMARY DOCUMENT
Director's Dealing
2018-08-02 English
PRIMARY DOCUMENT
Director's Dealing
2018-07-31 English
PRIMARY DOCUMENT
Director's Dealing
2018-07-27 English
FORM 6-K
Regulatory Filings
2018-07-27 English
Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)
Regulatory Filings Classification · 95% confidence The document is a press release dated July 27, 2018, announcing that Sandoz (a Novartis division) received European Commission approval for its biosimilar Hyrimoz® (adalimumab). It details the implications of the approval, clinical data summaries, and includes standard forward-looking statements and contact information for media/investor relations. This format is characteristic of an initial announcement of significant corporate news, specifically related to product approval and market access, which aligns best with an Earnings Release (ER) if it were financial results, or more generally, a Regulatory Filing (RNS) or a specific announcement type. Since it is a formal announcement of a regulatory/market event (EC approval) and not a full financial report (10-K, IR) or a management discussion (MDA), it fits the general category of a significant corporate announcement. Given the options, and since it is not a financial result release (ER) but a specific regulatory/product milestone announcement, the most appropriate general category for non-standard, important corporate news that isn't explicitly covered elsewhere is Regulatory Filings (RNS). However, if we consider the context of major corporate news dissemination, it functions similarly to an Earnings Release in terms of being a scheduled, high-impact announcement, but it is not about earnings. Since it is a formal press release announcing a major regulatory milestone, and RNS is the fallback for miscellaneous regulatory announcements, RNS is the best fit among the provided codes for this type of news release that isn't a financial report or a specific management/governance filing.
2018-07-27 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.